John Dawson appointed Senior Independent Director
Updated : 14:17
PRESS RELEASE
John Dawson CBE Appointed Senior Independent Director
Guildford, UK - 2 December 2022: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, today announces that John Dawson, CBE has been appointed Senior Independent Director of the Board with immediate effect. Mr Dawson has served as an independent Non-Executive Director and Chair of the Audit Committee of the Ergomed Board of Directors since March 2022.
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Richard Barfield (Chief Financial Officer) Keith Byrne (Senior Vice-President, Capital Markets & Strategy) | |
Numis (Nominated Advisor and Joint Broker) | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Euan Brown (Nominated Adviser) | |
James Black (Broker) | |
Peel Hunt LLP (Joint Broker) James Steel / Dr Christopher Golden |
Tel: +44 (0) 20 7418 8900
|
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Matthew Neal | |
Angela Gray | |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.